Navigation Links
Reportlinker Adds Bayer Schering Pharma AG: PharmaVitae Profile
Date:9/23/2010

NEW YORK, Sept. 23 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Bayer Schering Pharma AG: PharmaVitae Profile

http://www.reportlinker.com/p0201762/Bayer-Schering-Pharma-AG-PharmaVitae-Profile.html

Introduction

This analysis examines the historical and forecast performance for Bayer Schering in the prescription pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financi

ABOUT DATAMONITOR HEALTHCARE 2

About the PharmaVitae team 2

Chapter 1 About this profile 3

PharmaVitae Explorer database 3

Chapter structure 3

Executive summary 3

Quarterly update 3

Company introduction 3

Company sales 4

Company financials 4

Key products 4

Data sourcing 4

Sales data 4

Analyst consensus 4

Chapter 2 Executive summary 5

Key findings 5

Prescription pharmaceutical sales and growth rate performance, 2003-15 6

Financial performance, 2003-15 7

Bayer Schering Pharma: PharmaVitae forecasts at a glance 8

Strategic insight 9

Bayer's diversified structure is unusual within Big Pharma peer set 9

Weak revenue performance initiates restructuring strategy in 2003 9

Bayer's restructuring efforts have proved successful to date 10

Bayer's portfolio to drive prescription pharma growth over 2009-15 11

SWOT analysis 12

Strengths 12

Weaknesses 13

Opportunities 13

Threats 15

Table of Contents 16

Table of figures 18

Chapter 3 Quarterly news update 19

Latest quarterly sales 19

Latest comment 19

Q1 2010 19

Q4 2009 19

FIGO 2009: Bayer-Schering maintains leadership in contraception 19

Q3 2009 21

Q2 2009 21

Latest prescription pharma product news 22

Q1 2010 22

Q4 2009 22

Q3 2009 23

Q2 2009 25

Latest corporate news 26

Q1 2010 26

Q4 2009 27

Q3 2009 27

Q2 2009 27

Future product milestones 29

Chapter 4 Company introduction 31

Key findings 31

Background 32

Key corporate developments 32

Current corporate structure 33

Bayer Healthcare 33

Bayer MaterialScience 33

Bayer CropScience 34

Bayer Healthcare business unit structure 35

Bayer Schering Pharma 35

Prescription pharmaceuticals 35

Diagnostic imaging 35

Consumer Care 35

Animal Health 36

Medical Care 36

Medrad 36

Diabetes Care 36

M&A history 37

Acquisition of Roche Consumer Health AG (RCH) 37

Lanxess AG Spin-off 37

Divestment of US Plasma Products 38

Acquisition of Schering AG 38

Recent M&A promotes Bayer's healthcare focus 38

Divestment of Diagnostics Division 38

Divestment of H.C. Starck and Wolff Walsrode 39

Acquisition of Possis Medical and Sagmel Inc 39

M&A strategy 39

Chapter 5 Company sales 41

Key findings 41

Prescription pharmaceutical sales and growth rate analysis, 2003-15 42

Product analysis 45

Product analysis, 2003-09 46

Product analysis, 2009-15 49

Therapy area analysis 53

Geographic analysis 56

Launch/core/expiry analysis 59

Explanation of launch/core/expiry analysis 59

Launch analysis, 2009-15 60

Core analysis, 2009-15 62

Expiry analysis, 2009-15 64

Launch/core/expiry configuration, 2009-15 66

Molecule type analysis 67

Externalization analysis 70

Chapter 6 Company financials 73

Key findings 73

Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003-09 74

Operating costs and profit analysis 76

Operating costs and profit analysis, 2003-09 77

Operating cost ratio and profit margin analysis, 2003-09 79

Operating cost ratio and profit margin analysis, 2009-15 81

Operating costs and profit analysis, 2009-15 82

Chapter 7 Key products 83

Key findings 83

Overview 84

Xarelto 85

Overview 85

Sales forecast 86

A replacement for Warfarin? 86

Pradaxa is direct competitor 87

Nexavar 88

Overview 88

Sales forecast 89

Nexavar encounters strong competition in the RCC market 89

HCC market to offer better sales potential 89

Further indication broadening will boost sales growth 90

Mirena 91

Overview 91

Sales forecast 92

An alternative to sterilization 92

Key competitors 92

riociguat 94

Overview 94

Sales forecast 95

alpharadin 96

Overview 96

Sales forecast 97

Bayer co-development agreement with Algeta grants access to Alpharadin 97

Complementary nature indicates potential for combination therapy 97

Betaferon 98

Overview 98

Sales forecast 99

Betaferon: a success story despite initial challenges 99

Novartis agreement 99

Key competitors 100

Yaz 102

Overview 102

Sales forecast 103

The Impact of Yasmin's invalidated patent protection 103

New market launches 103

Ciprobay/Cipro 105

Overview 105

Sales forecast 106

Yasmin 107

Overview 107

Sales forecast 108

Yasmin: a historical growth driver 108

Yasmin patent invalidated following challenge from Barr Pharmaceuticals 108

The impact of generics 109

Key competitors 109

Chapter 8 Appendix 111

References 111

Abbreviations 111

Exchange rates 113

About Datamonitor 114

About Datamonitor Healthcare 114

Datamonitor consulting 114

Disclaimer 116

List of Tables

Table 1: Bayer Schering Pharma - PharmaVitae forecasts at a glance 8

Table 2: Bayer Schering Pharma quarterly sales ($m), Q408-Q409 19

Table 3: Bayer Schering Pharma future product milestones, 2010-12 29

Table 4: Bayer Schering Pharma product portfolio overview ($m), 2003-09 46

Table 5: Bayer Schering Pharma product portfolio overview ($m), 2009-15 49

Table 6: Bayer Schering Pharma prescription pharmaceutical sales by therapy area ($m), 2009-15 54

Table 7: Bayer Schering Pharma prescription pharmaceutical sales by geographic region ($m), 2009-15 57

Table 8: Bayer Schering Pharma launch portfolio overview ($m), 2009-15 60

Table 9: Bayer Schering Pharma core portfolio overview ($m), 2009-15 62

Table 10: Bayer Schering Pharma expiry portfolio overview ($m), 2009-15 64

Table 11: Bayer Schering Pharma prescription pharmaceutical sales by molecule type ($m), 2009-15 68

Table 12: Bayer Schering Pharma prescription pharmaceutical sales by source ($m), 2009-15 71

Table 13: Total Bayer Schering Pharma sales by business unit ($m), 2003-09 74

Table 14: Bayer Schering Pharma operating revenue/cost analysis ($m), 2003-09 77

Table 15: Bayer Schering Pharma operating cost ratio analysis (% of total revenues), 2003-09 79

Table 16: Bayer Schering Pharma operating cost ratio analysis (% of total revenues), 2009-15 81

Table 17: Bayer Schering Pharma operating revenue/cost analysis ($m), 2009-15 82

Table 18: Bayer Schering Pharma Key products overview 84

Table 19: Xarelto: overview 85

Table 20: Xarelto: sales forecast ($m), 2009-15 86

Table 21: Nexavar: overview 88

Table 22: Nexavar: sales forecast ($m), 2009-15 89

Table 23: Mirena: overview 91

Table 24: Mirena: sales forecast ($m), 2009-15 92

Table 25: riociguat: overview 94

Table 26: riociguat: sales forecast ($m), 2009-15 95

Table 27: alpharadin: overview 96

Table 28: alpharadin: sales forecast ($m), 2009-15 97

Table 29: Betaferon: overview 98

Table 30: Betaferon: sales forecast ($m), 2009-15 99

Table 31: Yaz: overview 102

Table 32: Yaz: sales forecast ($m), 2009-15 103

Table 33: Ciprobay/Cipro: overview 105

Table 34: Ciprobay/Cipro: sales forecast ($m), 2009-15 106

Table 35: Yasmin: overview 107

Table 36: Yasmin: sales forecast ($m), 2009-15 108

Table 37: Exchange rates, 2010 113

List of Figures

Figure 1: The PharmaVitae Explorer 3

Figure 2: Bayer Schering Pharma prescription pharmaceutical performance, sales ($m) and growth rate (%), 2003-15 6

Figure 3: Bayer Schering Pharma's financial performance ($m), 2003-15 7

Figure 4: Bayer AG, key acquisitions and divestments, 2003-09 10

Figure 5: Bayer Schering Pharma SWOT analysis 12

Figure 6: Current corporate structure 33

Figure 7: Bayer business unit structure by revenues, 2003-09, ($m) 35

Figure 8: Bayer key M&A and divestment events 37

Figure 9: Bayer Schering Pharma prescription pharmaceutical performance, sales ($m) and growth rate (%), 2003-15 43

Figure 10: Bayer Schering Pharma key product sales ($m), 2003-15 45

Figure 11: Bayer Schering Pharma key sales growth drivers and resistors ($m), 2003-09 48

Figure 12: Bayer Schering Pharma key sales growth drivers and resistors ($m), 2009-15 51

Figure 13: Bayer Schering Pharma prescription pharmaceutical sales by therapy area ($m), 2003-15 53

Figure 14: Bayer Schering Pharma prescription pharmaceutical sales by geographic region ($m), 2003-15 56

Figure 15: Bayer Schering Pharma launch/core/expiry configuration ($m), 2009-15 66

Figure 16: Bayer Schering Pharma prescription pharmaceutical sales by molecule type ($m), 2003-15 67

Figure 17: Bayer Schering Pharma prescription pharmaceutical sales by source ($m), 2003-15 70

Figure 18: Bayer Schering Pharma operating revenue/cost analysis ($m), 2003-15 76

To order this report:

Pharmaceutical Industry: Bayer Schering Pharma AG: PharmaVitae Profile

Pharmaceutical Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Genzyme Corporation: PharmaVitae Profile
2. Reportlinker Adds Multiple Sclerosis (MS) Drugs and Biologics: Technologies and Global Markets
3. Reportlinker Adds Spinal Surgical Devices: Technologies and Global Markets
4. Reportlinker Adds Actelion Ltd: PharmaVitae Profile
5. Reportlinker Adds Pfizer Inc.: PharmaVitae Profile
6. Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile
7. Reportlinker Adds Eli Lilly & Co.: PharmaVitae Profile
8. Reportlinker Adds E7: The Outlook for Pharmaceuticals to 2012
9. Reportlinker Adds The Impact of US Healthcare Reform on Pharma: Analyzing the Effects
10. Reportlinker Adds IP Overview - "Monoclonal Antibodies against digestive system cancers" Patent Landscape 2010
11. Reportlinker Adds Electrophysiology Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 2016  MiMedx Group, Inc. (NASDAQ: MDXG ), ... and other birth tissues, human skin and bone, and ... advanced products and therapies, announced today that it will ... Conference in New York , NY.  ... J. Senken , Chief Financial Officer and Chris ...
(Date:2/11/2016)... 11, 2016  AfterPill.com is reporting that this week,s ... for all women who are at risk of unintended ... year and raises the risks of unprotected sex in ... According to the Guttmacher Institute, there are 43 ... child-bearing age, who have sex without the intention of ...
(Date:2/11/2016)... Wearable posture tracker, ALEX , has taken Kickstarter by storm, crowdfunding over $60,000 – or 120% ... ALEX is said to be delivered to backers starting May of this year. ... ... ... Created by NAMU, a team of biomedical engineers out ...
Breaking Medicine Technology:
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... Image ... business to a new market, and it’s the buildings of Nashville that will benefit. ... when I needed to relocate to Nashville, there was no question that I would ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... advocates will discuss how to improve care by making data on heart procedures ... disease. The Summit on Transparency and Public Reporting of Pediatric and Congenital Heart ...
(Date:2/11/2016)... Plantation, Fla. (PRWEB) , ... February 11, 2016 ... ... CareTRAK™, an unparalleled clinical decision support technology, with highly adaptable algorithms, has ... cases. When a patient has signs and symptoms consistent with Zikas and a ...
(Date:2/11/2016)... ... February 11, 2016 , ... Life is known for ... men, 60 and older, who gather once a year to play softball to raise ... for the game, the more than 50 players who competed in this year’s softball ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... practice Village Family Practice , will be presenting at the 2016 HIMSS ... Las Vegas, Nev. , During his session, “ Coding for Care: Using ...
Breaking Medicine News(10 mins):